Abstracts tagged "SLE and apoptosis"

Abstract Number: 90 • 2018 ACR/ARHP Annual Meeting
Deoxyribonuclease 1-like-3 Digests Self-DNA from Dead Cells and Prevents Autoimmunity
Shoichiro Inokuchi¹, Hiroki Mitoma², Shotaro Kawano², Masahiro Ayano², Yasutaka Kimoto³, Mitsuteru Akahoshi², Yojiro Arinobu², Koichi Akashi², Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Deoxyribonuclease 1-like-3 (DNase1L3) belongs to Deoxyribonuclease 1(DNase1) family. This nuclease originally identified as one of apoptosis- and necrosis-related endonucleases that fragmentates intranucleosomal DNA. Unlike…
Abstract Number: 2193 • 2013 ACR/ARHP Annual Meeting
Altered Apoptosis Profile and Associated Soluble Factors In Patients With Juvenile-Onset Systemic Lupus Erythematosus
Bernadete Liphaus¹, Maria H. B. Kiss¹, Solange Carrasco² and Cláudia Goldenstein-Schainberg³, ¹Pediatria, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²University of São Paulo, São Paulo, Brazil, ³Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Apoptosis has been demonstrated to be involved in immune dysregulation and development of adult systemic lupus erythematosus (SLE) but less is known about its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].